Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
In Canada, lung cancer is the leading cause of cancer-related deaths for both sexes. Non-small-cell lung cancer (NSCLC) constitutes ~85% of lung cancer cases. Mutations in the KRAS and EGFR genes are two most common oncogenic drivers for NSCLC and responsible for ~30% and ~15% of NSCLCs, respectively. Unlike the EGFR-mutant type, KRAS-mutant NSCLC is currently undruggable and associated with poor prognosis. Our lab has recently demonstrated that Coxsackievirus B3 (CVB3) is a potent oncolytic virus against KRAS-mutant NSCLC. Nevertheless, it was observed that efficient tumor suppression is accompanied with damage to multiple organs, particularly the heart. Here we propose to develop an innovative CVB3-based oncolytic virus with enhanced tumor-specificity. If a therapeutic effect is achieved, the clinical significance may grant Virogin Biotech Ltd. one possibility to provide the first-ever effective and safe treatment for this deadly disease for Canadians.
Virogin Biotech Canada Ltd
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.